NeoGenomics Q2 Earnings Helped By Higher Test Volume; Backs FY21 Guidance
NeoGenomics Inc (NASDAQ:NEO) reported Q2 revenue of $122 million, +40% Y/Y, beating the consensus of $118.16 million. Clinical Services revenue…
Recap: NeoGenomics Q2 Earnings
Shares of NeoGenomics (NASDAQ:NEO) were unchanged after the company reported Q2 results.
Quarterly Results
Earnings per share were up 75.00% year over year to ($0.01), which beat the estimate of ($0.06).
NeoGenomics Q2 Adj. EPS $(0.01) Beats $(0.06) Estimate, Sales $122.00M Beat $118.16M Estimate
NeoGenomics (NASDAQ:NEO) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.06) by 83.33 percent. This is a 75 percent increase over losses of $(0.04) per share from the same
Earnings Scheduled For August 6, 2021
Companies Reporting Before The Bell
• Liberty Braves Group (NASDAQ:BATRA) is projected to report quarterly loss at $0.03 per share on revenue of $154.00 million.
NeoGenomics’s Earnings: A Preview
On Friday, August 06, NeoGenomics (NASDAQ:NEO) will release its latest earnings report. Here is Benzinga's outlook for the company.
Goldman Sachs Initiates Coverage On NeoGenomics with Buy Rating, Announces Price Target of $55
Goldman Sachs analyst Matthew Sykes initiates coverage on NeoGenomics (NASDAQ:NEO) with a Buy rating and announces Price Target of $55.
Earnings Scheduled For May 13, 2021
Companies Reporting Before The Bell
• CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million.
Earnings Scheduled For May 5, 2021
Companies Reporting Before The Bell
• Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter.